Acute Myeloid Leukemia
Conditions
Brief summary
JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia (AML) who are fit to receive intensive chemotherapy (ICT). Subjects will be assigned to treatment arms based on results of AML mutation testing.
Interventions
DRUGCPX-351
Up to 2 induction and 2 consolidation courses will be offered
DRUGVenetoclax
Will be administered over specified duration during induction and consolidation courses
DRUGMidostaurin
Will be administered over specified duration during induction and consolidation courses
DRUGEnasidenib
Will be administered over specified duration during induction and consolidation courses
Sponsors
Jazz Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 to ≤ 75 years at the time of informed consent. * Newly diagnosed AML according to World Health Organization (WHO) pathological criteria (with at least 20% blasts in the peripheral blood or bone marrow). * ECOG performance status of 0 to 2. * Laboratory values fulfilling the following: * Serum creatinine \< 2.0 mg/dL. * Serum total bilirubin \< 2.0 mg/dL. (For subjects with Gilbert's Syndrome and serum total bilirubin ≥ 2.0 mg/dL, the medical monitor should be contacted.) * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 times the upper limit of normal (ULN). (Note: If elevated liver enzymes \> ULN are related to disease, contact medical monitor to discuss.) * Cardiac ejection fraction ≥ 50% by echocardiography or multiple gated acquisition scan (MUGA). * Subjects with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period \> 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Subjects maintained on long-term nonchemotherapy treatment (eg, hormonal therapy) are eligible.
Exclusion criteria
* Acute promyelocytic leukemia \[t(15;17)\]. * Subject has favorable risk cytogenetics ((t8;21), inv(16), t(16;16), or t15;17) karyotype abnormalities) as categorized by the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2014 for AML (NCCN 2014). * Clinical evidence of active central nervous system (CNS) leukemia. * Subjects with active (uncontrolled, metastatic) second malignancies. * Subjects who have received prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood cell counts. (For example, a subject with myelodysplastic syndrome \[MDS\] who changes hypomethylating agent \[HMA\] dose and schedule after the diagnosis of AML is excluded. AML-type therapy, such as cytarabine alone \[\> 1g/m2/day\] or cytarabine plus an anthracycline as well as prior HSCT are also excluded.) All-trans-retinoic acid (ATRA) used empirically is permitted. * Subjects receiving administration of any therapy for MDS (conventional or investigational) must be completed by 2 weeks prior to the first dose of study drug. In the event of rapidly proliferative disease, use of hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to Grade 1 or less prior to start of treatment. * Subjects with myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging). * Subjects with active or uncontrolled infection. Subjects with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥ 72 hours. * Current evidence of invasive fungal infection (blood or tissue culture). Subjects with recent fungal infection must have a subsequent negative culture to be eligible. * Subjects with known human immunodeficiency virus (new testing not required) or evidence of active hepatitis B or C infection. * Subjects with known history of Wilson's disease or other known copper-metabolism disorder. * Subjects with other comorbidity that the investigator judges to be incompatible with conventional ICT, and / or the targeted agent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the Recommended Phase 2 Dose (RP2D) | Up to 30 months | The RP2D will be determined by the specified dose de-escalation/dose escalation algorithm. |
| Safety and Tolerability of CPX-351 and Targeted Agents: incidence of adverse events (AEs) and dose limiting toxicities (DLTs) | Up to 30 months | The safety and tolerability of CPX-351 and targeted agents when given in combination, based on the incidence of adverse events (AEs) and dose limiting toxicities (DLTs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects who have achieved CR, CRi, CRh, CR + CRi, CR + CRh, and morphologic leukemia-free state (MLFS) | Up to 30 months | After up to 2 inductions |
| Proportion of subjects who have achieved CR / CRi with MRD negative status | Up to 30 months | After up to 2 inductions |
| Proportion of subjects who have achieved CR / CRh with MRD negative status | Up to 30 months | After up to 2 inductions |
Countries
United States
Outcome results
None listed